| 2026-08-10 | Press release | Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase |
| 2026-07-10 | Press release | Palisade Bio to Participate in the Leerink Partners Therapeutics Forum |
| 2026-06-29 | Press release | Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcer |
| 2026-06-11 | Press release | Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors |
| 2026-06-09 | Press release | Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences |
| 2026-05-27 | Press release | Palisade Bio to Participate in the Jefferies Global Healthcare Conference |
| 2026-05-12 | Press release | Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 |
| 2026-05-05 | Press release | Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Suppor |
| 2026-04-16 | Press release | Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 |
| 2026-04-08 | Press release | Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference |
| 2026-04-07 | Presentation | Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease |
| 2026-03-30 | Press release | Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease |
| 2026-03-02 | Press release | Palisade Bio Announces Participation in Two Upcoming Investor Conferences |
| 2026-02-23 | Press release | Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted |
| 2026-02-17 | Press release | Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board |
| 2026-02-09 | Press release | Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium |
| 2026-02-05 | Press release | Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-01-29 | Press release | Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinic |
| 2026-01-16 | Press release | Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conf |
| 2026-01-07 | Press release | Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advan |
| 2025-12-30 | Press release | Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 |
| 2025-12-02 | Press release | Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical |
| 2025-11-25 | Press release | Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 2025-10-28 | Press release | Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations |
| 2025-10-20 | Press release | Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, |
| 2025-10-13 | Press release | Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 |
| 2025-10-09 | Press release | Palisade Bio Announces Cancellation of Special Meeting of Stockholders |
| 2025-10-02 | Press release | Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Ov |
| 2025-10-01 | Press release | Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock |
| 2025-09-26 | Press release | Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum |
| 2025-09-18 | Press release | Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum |
| 2025-09-17 | Press release | Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data |
| 2025-09-16 | Presentation | PALI-2108 Phase 1b Clinical Data |
| 2025-09-05 | Press release | Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) |
| 2025-08-25 | Press release | Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 |
| 2025-08-07 | Press release | Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 |
| 2025-07-31 | Press release | Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in |
| 2025-07-23 | Press release | Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million |
| 2025-07-22 | Press release | Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference |
| 2025-07-09 | Press release | Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors |